<![CDATA[Phase 1 trial shows promise for triple-negative breast cancer vaccine]]>
Key takeaways: A novel α-lactalbumin–targeting vaccine induced immune responses in 74% of participants in a phase 1 trial. The investigational vaccine demonstrated a favorable safety and tolerability profile across all study cohorts. Three distinct phase 1 …